Zanidatamab is a medication designed to target HER2, a protein that can be overexpressed in certain types of cancer. It is an antibody-based therapy that works by attaching to HER2 proteins on cancer cells, helping to stop or slow down cancer growth. This medication is being studied in patients who have various types of solid tumors that either have too much HER2 protein or mutations in the HER2 gene.

Endometrial cancer – A cancer that begins in the lining of the uterus (endometrium). It typically develops when cells in the endometrium start growing abnormally and form a tumor. The disease most commonly occurs in women after menopause.

Colorectal cancer – A cancer that starts in the large intestine (colon) or rectum. It typically begins as small, benign clumps of cells called polyps that over time can become cancerous. The disease develops gradually and affects the digestive system.

Head and neck cancer – A group of cancers that starts in the tissues and organs of the head and neck area. These cancers can begin in the mouth, throat, voice box, nasal cavity, or sinuses. The disease affects the upper parts of the digestive and respiratory tracts.

Sarcoma – A rare type of cancer that develops in the body’s connective tissues. It can occur in bones, muscles, tendons, cartilage, nerves, fat, and blood vessels. The disease can develop anywhere in the body.

Non-small cell lung cancer – A type of lung cancer that forms in the tissues of the lung. It is the most common type of lung cancer, developing in the cells that line the air passages. The disease typically grows and spreads more slowly than small cell lung cancer.